UniProtKB/Swiss-Prot P35240: Variant p.Leu141Pro

Merlin
Gene: NF2
Chromosomal location: 22q12.2
Variant information

Variant position:  141
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants have been found in patients and disease-association is reported in literature. However, this classification is not a definitive assessment of variant pathogenicity.
  • Polymorphism: No disease-association has been reported.
  • Unclassified: Variants have been found in patients but disease-association remains unclear.

Residue change:  From Leucine (L) to Proline (P) at position 141 (L141P, p.Leu141Pro).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In NF2; loss of ability to interact with the CUL4A-RBX1-DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex.
Any additional useful information about the variant.



Sequence information

Variant position:  141
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  595
The length of the canonical sequence.

Location on the sequence:   QVKKQILDEKIYCPPEASVL  L ASYAVQAKYGDYDPSVHKRG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         QVKKQILDEKIYCPPEASVLLASYAVQAKYGDYDPSVHKRG

Mouse                         QVKKQILDEKVYCPPEASVLLASYAVQAKYGDYDPSVHKRG

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 595 Merlin
Domain 22 – 311 FERM
Helix 135 – 150


Literature citations

Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.
Li W.; You L.; Cooper J.; Schiavon G.; Pepe-Caprio A.; Zhou L.; Ishii R.; Giovannini M.; Hanemann C.O.; Long S.B.; Erdjument-Bromage H.; Zhou P.; Tempst P.; Giancotti F.G.;
Cell 140:477-490(2010)
Cited for: FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH VPRBP AND THE CUL4A-RBX1-DDB1-VPRBP/DCAF1 E3 UBIQUITIN-PROTEIN LIGASE COMPLEX; PHOSPHORYLATION; MUTAGENESIS OF LEU-64 AND SER-518; CHARACTERIZATION OF VARIANT ARG-46; CHARACTERIZATION OF VARIANTS NF2 SER-62 AND PRO-141;

Preimplantation diagnosis for neurofibromatosis.
Verlinsky Y.; Rechitsky S.; Verlinsky O.; Chistokhina A.; Sharapova T.; Masciangelo C.; Levy M.; Kaplan B.; Lederer K.; Kuliev A.;
Reprod. BioMed. Online 4:218-222(2002)
Cited for: VARIANT NF2 PRO-141;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.